Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen

Biodexa Pharmaceuticals (NASDAQ:BDRX) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Price Performance

BDRX opened at $1.16 on Friday. The stock’s 50-day moving average price is $2.29 and its 200 day moving average price is $4.84. Biodexa Pharmaceuticals has a 12-month low of $1.04 and a 12-month high of $44.40.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC purchased a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for about 0.6% of Sabby Management LLC’s portfolio, making the stock its 10th largest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.